Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.

Basler M, Lindstrom MM, LaStant JJ, Bradshaw JM, Owens TD, Schmidt C, Maurits E, Tsu C, Overkleeft HS, Kirk CJ, Langrish CL, Groettrup M.

EMBO Rep. 2018 Oct 2. pii: e46512. doi: 10.15252/embr.201846512. [Epub ahead of print]

PMID:
30279279
2.

Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation.

Li J, Basler M, Alvarez G, Brunner T, Kirk CJ, Groettrup M.

Kidney Int. 2018 Mar;93(3):670-680. doi: 10.1016/j.kint.2017.09.023. Epub 2017 Dec 8.

PMID:
29229189
3.

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.

Lee SJ, Levitsky K, Parlati F, Bennett MK, Arastu-Kapur S, Kellerman L, Woo TF, Wong AF, Papadopoulos KP, Niesvizky R, Badros AZ, Vij R, Jagannath S, Siegel D, Wang M, Ahmann GJ, Kirk CJ.

Br J Haematol. 2016 Jun;173(6):884-95. doi: 10.1111/bjh.14014. Epub 2016 Apr 12.

4.

Inhibition and deficiency of the immunoproteasome subunit LMP7 attenuates LCMV-induced meningitis.

Mundt S, Engelhardt B, Kirk CJ, Groettrup M, Basler M.

Eur J Immunol. 2016 Jan;46(1):104-13. doi: 10.1002/eji.201545578. Epub 2015 Nov 2.

5.

Inhibition of the Immunoproteasome Subunit LMP7 with ONX 0914 Ameliorates Graft-versus-Host Disease in an MHC-Matched Minor Histocompatibility Antigen-Disparate Murine Model.

Zilberberg J, Matos J, Dziopa E, Dziopa L, Yang Z, Kirk CJ, Assefnia S, Korngold R.

Biol Blood Marrow Transplant. 2015 Sep;21(9):1555-64. doi: 10.1016/j.bbmt.2015.06.010. Epub 2015 Jun 18.

6.
7.

Assessment of cytokine-modulated proteasome activity.

Kirk CJ, Powell SR, Miller EJ.

Methods Mol Biol. 2014;1172:147-62. doi: 10.1007/978-1-4939-0928-5_13.

PMID:
24908302
8.

Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.

Niewerth D, van Meerloo J, Jansen G, Assaraf YG, Hendrickx TC, Kirk CJ, Anderl JL, Zweegman S, Kaspers GJ, Cloos J.

Biochem Pharmacol. 2014 May 1;89(1):43-51. doi: 10.1016/j.bcp.2014.02.005. Epub 2014 Feb 16.

PMID:
24552657
9.

A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.

Eda H, Santo L, Cirstea DD, Yee AJ, Scullen TA, Nemani N, Mishima Y, Waterman PR, Arastu-Kapur S, Evans E, Singh J, Kirk CJ, Westlin WF, Raje NS.

Leukemia. 2014 Sep;28(9):1892-901. doi: 10.1038/leu.2014.69. Epub 2014 Feb 12.

PMID:
24518207
10.

Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.

Niewerth D, Kaspers GJ, Assaraf YG, van Meerloo J, Kirk CJ, Anderl J, Blank JL, van de Ven PM, Zweegman S, Jansen G, Cloos J.

J Hematol Oncol. 2014 Jan 13;7:7. doi: 10.1186/1756-8722-7-7.

11.

Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis.

Basler M, Mundt S, Muchamuel T, Moll C, Jiang J, Groettrup M, Kirk CJ.

EMBO Mol Med. 2014 Feb;6(2):226-38. doi: 10.1002/emmm.201303543. Epub 2014 Jan 16.

12.

Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.

Niewerth D, Franke NE, Jansen G, Assaraf YG, van Meerloo J, Kirk CJ, Degenhardt J, Anderl J, Schimmer AD, Zweegman S, de Haas V, Horton TM, Kaspers GJ, Cloos J.

Haematologica. 2013 Dec;98(12):1896-904. doi: 10.3324/haematol.2013.092411. Epub 2013 Sep 20.

13.

Reactive glia show increased immunoproteasome activity in Alzheimer's disease.

Orre M, Kamphuis W, Dooves S, Kooijman L, Chan ET, Kirk CJ, Dimayuga Smith V, Koot S, Mamber C, Jansen AH, Ovaa H, Hol EM.

Brain. 2013 May;136(Pt 5):1415-31. doi: 10.1093/brain/awt083. Epub 2013 Apr 19.

PMID:
23604491
14.

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.

Verbrugge SE, Al M, Assaraf YG, Niewerth D, van Meerloo J, Cloos J, van der Veer M, Scheffer GL, Peters GJ, Chan ET, Anderl JL, Kirk CJ, Zweegman S, Dijkmans BA, Lems WF, Scheper RJ, de Gruijl TD, Jansen G.

Exp Hematol Oncol. 2013 Jan 10;2(1):2. doi: 10.1186/2162-3619-2-2.

15.

The immunoproteasome in antigen processing and other immunological functions.

Basler M, Kirk CJ, Groettrup M.

Curr Opin Immunol. 2013 Feb;25(1):74-80. doi: 10.1016/j.coi.2012.11.004. Epub 2012 Dec 6. Review.

PMID:
23219269
16.

Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity.

Li H, Ponder EL, Verdoes M, Asbjornsdottir KH, Deu E, Edgington LE, Lee JT, Kirk CJ, Demo SD, Williamson KC, Bogyo M.

Chem Biol. 2012 Dec 21;19(12):1535-45. doi: 10.1016/j.chembiol.2012.09.019. Epub 2012 Nov 8.

17.

The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.

Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE.

Autophagy. 2012 Dec;8(12):1873-4. doi: 10.4161/auto.22185. Epub 2012 Sep 20.

18.

Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation.

Kalim KW, Basler M, Kirk CJ, Groettrup M.

J Immunol. 2012 Oct 15;189(8):4182-93. doi: 10.4049/jimmunol.1201183. Epub 2012 Sep 14.

19.

Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.

Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE.

Clin Cancer Res. 2012 Oct 15;18(20):5639-49. doi: 10.1158/1078-0432.CCR-12-1213. Epub 2012 Aug 28.

20.

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN.

Leukemia. 2013 Feb;27(2):430-40. doi: 10.1038/leu.2012.183. Epub 2012 Jul 5.

21.

Discovery and development of second-generation proteasome inhibitors.

Kirk CJ.

Semin Hematol. 2012 Jul;49(3):207-14. doi: 10.1053/j.seminhematol.2012.04.007. Review.

PMID:
22726543
22.

Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity.

Huber EM, Basler M, Schwab R, Heinemeyer W, Kirk CJ, Groettrup M, Groll M.

Cell. 2012 Feb 17;148(4):727-38. doi: 10.1016/j.cell.2011.12.030.

23.

Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.

Verbrugge SE, Assaraf YG, Dijkmans BA, Scheffer GL, Al M, den Uyl D, Oerlemans R, Chan ET, Kirk CJ, Peters GJ, van der Heijden JW, de Gruijl TD, Scheper RJ, Jansen G.

J Pharmacol Exp Ther. 2012 Apr;341(1):174-82. doi: 10.1124/jpet.111.187542. Epub 2012 Jan 10.

24.

Molecular mechanisms of bortezomib resistant adenocarcinoma cells.

Suzuki E, Demo S, Deu E, Keats J, Arastu-Kapur S, Bergsagel PL, Bennett MK, Kirk CJ.

PLoS One. 2011;6(12):e27996. doi: 10.1371/journal.pone.0027996. Epub 2011 Dec 22.

25.

Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.

de Wilt LH, Jansen G, Assaraf YG, van Meerloo J, Cloos J, Schimmer AD, Chan ET, Kirk CJ, Peters GJ, Kruyt FA.

Biochem Pharmacol. 2012 Jan 15;83(2):207-17. doi: 10.1016/j.bcp.2011.10.009. Epub 2011 Oct 18.

PMID:
22027222
26.

The antiviral immune response in mice devoid of immunoproteasome activity.

Basler M, Beck U, Kirk CJ, Groettrup M.

J Immunol. 2011 Dec 1;187(11):5548-57. doi: 10.4049/jimmunol.1101064. Epub 2011 Oct 19.

27.

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.

Franke NE, Niewerth D, Assaraf YG, van Meerloo J, Vojtekova K, van Zantwijk CH, Zweegman S, Chan ET, Kirk CJ, Geerke DP, Schimmer AD, Kaspers GJ, Jansen G, Cloos J.

Leukemia. 2012 Apr;26(4):757-68. doi: 10.1038/leu.2011.256. Epub 2011 Sep 23.

PMID:
21941364
28.

Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.

Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, Barnard J, Nevarez S, Goldman BI, Kirk CJ, Looney RJ, Anolik JH.

Arthritis Rheum. 2012 Feb;64(2):493-503. doi: 10.1002/art.33333. Erratum in: Arthritis Rheum. 2012 Mar;64(3):939.

29.

Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats.

Yang J, Wang Z, Fang Y, Jiang J, Zhao F, Wong H, Bennett MK, Molineaux CJ, Kirk CJ.

Drug Metab Dispos. 2011 Oct;39(10):1873-82. doi: 10.1124/dmd.111.039164. Epub 2011 Jul 13.

30.

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.

Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ, Kirk CJ.

Clin Cancer Res. 2011 May 1;17(9):2734-43. doi: 10.1158/1078-0432.CCR-10-1950. Epub 2011 Mar 1.

31.

PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo.

Singh AV, Bandi M, Aujay MA, Kirk CJ, Hark DE, Raje N, Chauhan D, Anderson KC.

Br J Haematol. 2011 Jan;152(2):155-63. doi: 10.1111/j.1365-2141.2010.08491.x. Epub 2010 Nov 29.

32.

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.

Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, Raje N, Richardson P, Anderson KC.

Blood. 2010 Dec 2;116(23):4906-15. doi: 10.1182/blood-2010-04-276626. Epub 2010 Aug 30.

33.

Prevention of experimental colitis by a selective inhibitor of the immunoproteasome.

Basler M, Dajee M, Moll C, Groettrup M, Kirk CJ.

J Immunol. 2010 Jul 1;185(1):634-41. doi: 10.4049/jimmunol.0903182. Epub 2010 Jun 4.

34.

Developing laboratory networks: a practical guide and application.

Kirk CJ, Shult PA.

Public Health Rep. 2010 May-Jun;125 Suppl 2:102-9.

35.

Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs.

Coughlin JE, Padmanabhan S, Zhang G, Kirk CJ, Govardhan CP, Korba BE, O'Loughlin K, Green CE, Mirsalis J, Morrey JD, Iyer RP.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1783-6. doi: 10.1016/j.bmcl.2010.01.010. Epub 2010 Jan 11.

36.

Proteasomes in immune cells: more than peptide producers?

Groettrup M, Kirk CJ, Basler M.

Nat Rev Immunol. 2010 Jan;10(1):73-8. doi: 10.1038/nri2687. Epub 2009 Dec 11. Review.

PMID:
20010787
37.

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis.

Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, Shwonek P, Parlati F, Demo SD, Bennett MK, Kirk CJ, Groettrup M.

Nat Med. 2009 Jul;15(7):781-7. doi: 10.1038/nm.1978. Epub 2009 Jun 14. Erratum in: Nat Med. 2009 Nov;15(11):1333.

PMID:
19525961
38.

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, Ho MN, Jiang J, Kirk CJ, Laidig GJ, Lewis ER, Lu Y, Muchamuel T, Parlati F, Ring E, Shenk KD, Shields J, Shwonek PJ, Stanton T, Sun CM, Sylvain C, Woo TM, Yang J.

J Med Chem. 2009 May 14;52(9):3028-38. doi: 10.1021/jm801329v.

PMID:
19348473
39.

Inhibition of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase by flavonoids: a quantitative structure-activity relationship study.

Ogunbayo OA, Harris RM, Waring RH, Kirk CJ, Michelangeli F.

IUBMB Life. 2008 Dec;60(12):853-8. doi: 10.1002/iub.132.

40.

Endocrine disrupting alkylphenols: structural requirements for their adverse effects on Ca2+ pumps, Ca2+ homeostasis & Sertoli TM4 cell viability.

Michelangeli F, Ogunbayo OA, Wootton LL, Lai PF, Al-Mousa F, Harris RM, Waring RH, Kirk CJ.

Chem Biol Interact. 2008 Nov 25;176(2-3):220-6. doi: 10.1016/j.cbi.2008.08.005. Epub 2008 Aug 19.

PMID:
18773882
41.

Development of proteasome inhibitors in oncology and autoimmune diseases.

Bennett MK, Kirk CJ.

Curr Opin Drug Discov Devel. 2008 Sep;11(5):616-25. Review.

PMID:
18729013
42.

On the internal perceptual structure of distinctive features: The [voice] contrast.

Kingston J, Diehl RL, Kirk CJ, Castleman WA.

J Phon. 2008 Jan 1;36(1):28-54.

43.

Phytoestrogens and xenoestrogens: the contribution of diet and environment to endocrine disruption.

Waring RH, Ayers S, Gescher AJ, Glatt HR, Meinl W, Jarratt P, Kirk CJ, Pettitt T, Rea D, Harris RM.

J Steroid Biochem Mol Biol. 2008 Feb;108(3-5):213-20. Epub 2007 Sep 7. Review.

PMID:
17933522
44.

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK.

Cancer Res. 2007 Jul 1;67(13):6383-91.

45.

Substrate characterisation of a recombinant sulfotransferase SULT1 and mRNA expression in chub (Leuciscus cephalus) tissues.

Assem FL, Kirk CJ, Chipman JK.

Biochem Biophys Res Commun. 2006 Oct 27;349(3):900-5. Epub 2006 Aug 28.

PMID:
16962072
46.

Bidirectional interactions between viral respiratory illnesses and cytokine responses in the first year of life.

Gern JE, Brooks GD, Meyer P, Chang A, Shen K, Evans MD, Tisler C, Dasilva D, Roberg KA, Mikus LD, Rosenthal LA, Kirk CJ, Shult PA, Bhattacharya A, Li Z, Gangnon R, Lemanske RF Jr.

J Allergy Clin Immunol. 2006 Jan;117(1):72-8. Epub 2005 Nov 28.

PMID:
16387587
47.

Anti-HBV nucleotide prodrug analogs: synthesis, bioreversibility, and cytotoxicity studies.

Padmanabhan S, Coughlin JE, Zhang G, Kirk CJ, Iyer RP.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1491-4. Epub 2006 Jan 4.

PMID:
16387496
48.

Viral infections, cytokine dysregulation and the origins of childhood asthma and allergic diseases.

Friedlander SL, Jackson DJ, Gangnon RE, Evans MD, Li Z, Roberg KA, Anderson EL, Carlson-Dakes KT, Adler KJ, Gilbertson-White S, Pappas TE, Dasilva DF, Tisler CJ, Pleiss LE, Mikus LD, Rosenthal LA, Shult PA, Kirk CJ, Reisdorf E, Hoffjan S, Gern JE, Lemanske RF Jr.

Pediatr Infect Dis J. 2005 Nov;24(11 Suppl):S170-6, discussion S174-5. Review.

PMID:
16378042
49.

Non-genomic effects of endocrine disrupters: inhibition of estrogen sulfotransferase by phenols and chlorinated phenols.

Harris RM, Kirk CJ, Waring RH.

Mol Cell Endocrinol. 2005 Dec 1;244(1-2):72-4. Epub 2005 Nov 2.

PMID:
16266779
50.

Rhinovirus illnesses during infancy predict subsequent childhood wheezing.

Lemanske RF Jr, Jackson DJ, Gangnon RE, Evans MD, Li Z, Shult PA, Kirk CJ, Reisdorf E, Roberg KA, Anderson EL, Carlson-Dakes KT, Adler KJ, Gilbertson-White S, Pappas TE, Dasilva DF, Tisler CJ, Gern JE.

J Allergy Clin Immunol. 2005 Sep;116(3):571-7.

PMID:
16159626

Supplemental Content

Support Center